Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15863219 | 0.96 | SLC6A3 (0.58) | SLC6A4SLC6A3SLC6A2OPRM1EPHX2 | |
| SCHEMBL16554261 | 0.84 | DRD2 (0.50) | SLC6A4SLC6A3SLC6A2OPRM1CYP3A4 | |
| SCHEMBL16553950 | 0.83 | SLC6A4 (0.41) | SLC6A4SLC6A3SLC6A2OPRM1EPHX2 | |
| SCHEMBL19226369 | 0.82 | OPRM1 (0.59) | SLC6A4OPRM1KCNH2 | |
| SCHEMBL21078138 | 0.82 | OPRM1 (0.41) | SLC6A4SLC6A3SLC6A2OPRM1EPHX2 | |
| SCHEMBL17339732 | 0.81 | OPRM1 (0.40) | SLC6A4SLC6A3SLC6A2OPRM1TSHR | |
| SCHEMBL8319137 | 0.81 | TSHR (0.53) | SLC6A4SLC6A3SLC6A2OPRM1EPHX2 | |
| SCHEMBL11103974 | 0.81 | SLC6A4 (0.63) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL16553736 | 0.80 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2OPRM1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31491278 | 0.79 | SLC6A4 (0.42) | SLC6A4SLC6A3SLC6A2OPRM1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2021-05-06 | — | — | US | disclosed |
| EP-2268140-B1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-2066329-B1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOBUTYLMETHYLAMINES | REVIVA PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9302981-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9206143-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8669285-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130231386-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445714-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2066329-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | Reviva Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | REVIVA PHARMACEUTICALS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008034142-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-4814352-A | ANTIDEPRESSANT CYCLOBUTYL BENZYLAMINE | THE BOOTS COMPANY PLC (GB) | 1989-03-21 | — | — | US | disclosed |
| US-4806570-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1989-02-21 | — | — | US | disclosed |
| US-4767790-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1988-08-30 | — | — | US | disclosed |
| US-4746680-A | ANTIDEPRESSANTS | THE BOOTS COMPANY P.L.C. (GB) | 1988-05-24 | — | — | US | disclosed |
| US-4522828-A | CYCLOBUTYLALKYLAMINE COMPOUNDS, ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1985-06-11 | — | — | US | disclosed |
| US-4443449-A | Arylcyclobutylalkylamines and anti-depression composition and methods using same | THE BOOTS COMPANY LIMITED (GB) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | SLC6A4 288/4885SLC6A3 167/4885SLC6A2 278/4885 |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GAP43, CHRNA10, CHRNA6 | SLC6A4 149/4885SLC6A3 59/4885SLC6A2 105/4885 |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | AADAC, INMT, AADAT | SLC6A4 229/4885SLC6A3 541/4885SLC6A2 925/4885 |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | SLC6A4 305/4885SLC6A3 163/4885SLC6A2 273/4885 |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | AADAC, GPR119, MC4R | SLC6A4 108/4885SLC6A3 204/4885SLC6A2 317/4885 |
| US-20130231386-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | AADAC, INMT, AADAT | SLC6A4 229/4885SLC6A3 541/4885SLC6A2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.